PCVX
Vaxcyte, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+74/100
Last price
66.70
▼ 7.12 (9.65%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
70.81
Prev close
73.82
Day high
73.40
Day low
63.90
Volume
10.16M
Market cap
$9.93B
P/E (TTM)
—
52W range
39.87 – 90.75
Day trading desk
Gap from prior close
-4.08%
Prior close 73.82
VWAP
65.85
+1.29% from price
Relative volume
13.92×
Unusually busy
Session range
15.01%
63.90 – 73.49
Position in range
29%
Near session low
ATR (14D)
5.17
7.75% of price
Prior day high
90.75
PDH
Prior day low
71.60
PDL
Bid / ask spread
—
Quote not published
Session volume
19.03M
Avg 1.37M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+17.66%
+15.7%
1M
+9.06%
+7.9%
3M
+13.61%
+9.1%
6M
+9.90%
-8.3%
YTD
+44.56%
+30.3%
1Y
+56.35%
+39.9%
3Y
+30.84%
-51.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PCVX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+10.03K
Net buying
Buy transactions
19
142.12K shares
Sell transactions
14
132.09K shares
Net transactions
+33
Buys less sells
Sell : buy shares
0.9 : 1
Mixed
Insider-held shares
741.05K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 9, 26 | WASSIL JAMES Chief Operating Officer |
SELL | 2.71K | $163.86K | Direct |
| Sep 4, 26 | JODAR LUIS Officer |
STOCK | 52.63K | $0 | Direct |
| Sep 1, 26 | WASSIL JAMES Chief Operating Officer |
SELL | 3.48K | $212.35K | Direct |
| Sep 1, 26 | WASSIL JAMES Chief Operating Officer |
CONVERSION | 2.25K | $12.04K | Direct |
| Aug 5, 26 | DHALIWAL HARPREET S. Officer |
SELL | 17.00K | $935.07K | Direct |
| Aug 5, 26 | DHALIWAL HARPREET S. Officer |
CONVERSION | 17.00K | $421.43K | Direct |
| Aug 3, 26 | GUGGENHIME ANDREW President |
SELL | 10.00K | $538.88K | Direct |
| Aug 3, 26 | GUGGENHIME ANDREW President |
CONVERSION | 10.00K | $53.50K | Direct |
| Aug 3, 26 | WASSIL JAMES Chief Operating Officer |
SELL | 2.25K | $121.19K | Direct |
| Aug 3, 26 | WASSIL JAMES Chief Operating Officer |
CONVERSION | 2.25K | $12.04K | Direct |
| Jul 27, 26 | PICKERING GRANT E Chief Executive Officer |
SELL | 18.20K | $1.01M | |
| Jul 27, 26 | PICKERING GRANT E Chief Executive Officer |
CONVERSION | 16.20K | $32.88K | Direct |
| Jul 6, 26 | GUGGENHIME ANDREW President |
SELL | 10.00K | $572.84K | Direct |
| Jul 6, 26 | GUGGENHIME ANDREW President |
CONVERSION | 10.00K | $53.50K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
COWAN ELVIA |
Officer | 28.98K | Sale |
DHALIWAL HARPREET S. |
Officer | 76.76K | Sale |
EYDELMAN MIKHAIL |
General Counsel | 41.62K | Sale |
GUGGENHIME ANDREW |
President | 167.03K | Sale |
JODAR LUIS |
Officer | 52.63K | Stock Award(Grant) |
LOXAM TERI |
Director | 12.48K | Stock Award(Grant) |
LUKATCH HEATH SCOTT |
Director | 19.48K | Stock Award(Grant) |
PAYA CARLOS V |
Director | 12.48K | Stock Award(Grant) |
PICKERING GRANT E |
Chief Executive Officer | — | Sale |
WASSIL JAMES |
Chief Operating Officer | 145.44K | Sale |
Fundamentals
Market cap$9.93B
Enterprise value$8.55B
Revenue (TTM)—
Gross profit—
EBITDA$-1.15B
Net income$-1.06B
EPS (TTM)$-6.88
Free cash flow$-485.76M
Total cash$1.49B
Total debt$115.44M
Book value / share$19.05
Shares outstanding148.81M
Float136.44M
Short % of float10.90%
Dividend yield0.00%
Beta (5Y)1.23
Valuation & profitability ratios
Trailing P/E—
Forward P/E-8.86
PEG ratio—
Price / sales—
Price / book3.50
EV / revenue—
EV / EBITDA-7.45
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-36.51%
Return on assets-22.61%
Debt / equity4.19
Current ratio5.72
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $794.31M | $476.64M | $332.34M | $169.45M | +66.6% |
| Selling, general & admin | $129.37M | $92.90M | $60.70M | $39.81M | +39.3% |
| Total operating expense | $923.67M | $569.55M | $393.04M | $209.26M | +62.2% |
| Operating income | -$923.67M | -$569.55M | -$393.04M | -$209.26M | -62.2% |
| Net interest income | $119.72M | $109.99M | $62.91M | $8.35M | +8.8% |
| Pre-tax income | -$766.63M | -$463.93M | -$402.27M | -$223.49M | -65.2% |
| Net income | -$766.63M | -$463.93M | -$402.27M | -$223.49M | -65.2% |
| Net income to common | -$766.63M | -$463.93M | -$402.27M | -$223.49M | -65.2% |
| Basic EPS | -5.63 | -3.80 | -4.14 | -3.44 | -48.2% |
| Diluted EPS | -5.63 | -3.80 | -4.14 | -3.44 | -48.2% |
| EBIT | -$923.67M | -$569.55M | -$393.04M | -$223.48M | -62.2% |
| EBITDA | -$898.82M | -$553.70M | -$382.87M | -$214.03M | -62.3% |
| Basic shares | 136.09M | 122.00M | 97.16M | 64.88M | +11.6% |
| Diluted shares | 136.09M | 122.00M | 97.16M | 64.88M | +11.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $173.96M | $387.88M | $397.45M | $834.66M | -55.2% |
| Cash & short-term investments | $1.56B | $1.75B | $1.08B | $931.38M | -10.7% |
| Total current assets | $1.63B | $1.79B | $1.10B | $942.55M | -9.0% |
| Property, plant & equipment | $491.72M | $332.62M | $145.31M | $31.65M | +47.8% |
| Total assets | $3.00B | $3.51B | $1.41B | $1.01B | -14.5% |
| Total current liabilities | $205.75M | $140.18M | $145.34M | $40.52M | +46.8% |
| Total debt | $117.48M | $71.11M | $29.22M | $17.94M | +65.2% |
| Total liabilities | $317.21M | $205.50M | $167.45M | $52.56M | +54.4% |
| Retained earnings | -$2.15B | -$1.39B | -$924.39M | -$522.13M | -55.2% |
| Shareholder equity | $2.69B | $3.31B | $1.24B | $953.61M | -18.8% |
| Working capital | $1.42B | $1.65B | $950.62M | $902.03M | -13.7% |
| Net tangible assets | $2.69B | $3.31B | $1.24B | $953.61M | -18.8% |
| Shares issued | 131.06M | 124.89M | 95.36M | 79.47M | +4.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$766.63M | -$463.93M | -$402.27M | -$223.49M | -65.2% |
| Depreciation & amortisation | $24.86M | $15.85M | $10.17M | $9.45M | +56.9% |
| Stock-based compensation | $138.84M | $84.82M | $48.76M | $23.65M | +63.7% |
| Change in working capital | -$3.45M | -$54.90M | $81.32M | $12.74M | +93.7% |
| Operating cash flow | -$655.58M | -$452.63M | -$296.79M | -$170.60M | -44.8% |
| Capital expenditure | -$56.97M | -$119.16M | -$67.88M | -$5.84M | +52.2% |
| Investing cash flow | $437.35M | -$2.01B | -$773.31M | $74.58M | +121.8% |
| Financing cash flow | $2.01M | $2.45B | $639.81M | $861.55M | -99.9% |
| Free cash flow | -$712.55M | -$571.79M | -$364.67M | -$176.44M | -24.6% |
| End cash position | $175.43M | $389.19M | $398.55M | $835.53M | -54.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $267.85M | $312.78M | $242.06M | $209.93M | $194.18M | — | -14.4% |
| Selling, general & admin | $34.92M | $33.07M | $32.22M | $32.45M | $32.04M | — | +5.6% |
| Total operating expense | $302.78M | $345.85M | $274.28M | $242.38M | $226.22M | — | -12.5% |
| Operating income | -$302.78M | -$345.85M | -$274.28M | -$242.38M | -$226.22M | — | +12.5% |
| Net interest income | $25.75M | $26.61M | $26.45M | $29.26M | $31.07M | — | -3.2% |
| Pre-tax income | -$284.30M | -$320.62M | -$246.51M | -$212.83M | -$166.57M | — | +11.3% |
| Net income | -$284.30M | -$320.62M | -$246.51M | -$212.83M | -$166.57M | — | +11.3% |
| Net income to common | -$284.30M | -$320.62M | -$246.51M | -$212.83M | -$166.57M | — | +11.3% |
| Basic EPS | -1.97 | -2.30 | — | -1.56 | -1.22 | -1.04 | +14.3% |
| Diluted EPS | -1.97 | -2.30 | — | -1.56 | -1.22 | -1.04 | +14.3% |
| EBIT | -$302.78M | -$345.85M | -$274.28M | -$242.38M | -$226.22M | — | +12.5% |
| EBITDA | -$296.85M | -$340.00M | -$264.48M | -$237.18M | -$221.23M | — | +12.7% |
| Basic shares | 144.49M | 139.51M | — | 136.20M | 136.03M | 135.69M | +3.6% |
| Diluted shares | 144.49M | 139.51M | — | 136.20M | 136.03M | 135.69M | +3.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $183.19M | $260.84M | $173.96M | $281.08M | $306.74M | -29.8% |
| Cash & short-term investments | $1.49B | $1.74B | $1.56B | $1.71B | $1.66B | -14.4% |
| Total current assets | $1.55B | $1.81B | $1.63B | $1.77B | $1.72B | -14.4% |
| Property, plant & equipment | $370.57M | $373.80M | $491.72M | $337.00M | $327.92M | -0.9% |
| Total assets | $3.14B | $3.35B | $3.00B | $3.17B | $3.31B | -6.3% |
| Total current liabilities | $271.28M | $242.08M | $205.75M | $200.05M | $154.49M | +12.1% |
| Total debt | $115.44M | $116.30M | $117.48M | $84.44M | $85.84M | -0.7% |
| Total liabilities | $380.21M | $352.29M | $317.21M | $278.72M | $234.03M | +7.9% |
| Retained earnings | -$2.76B | -$2.48B | -$2.15B | -$1.91B | -$1.70B | -11.5% |
| Shareholder equity | $2.76B | $3.00B | $2.69B | $2.89B | $3.07B | -7.9% |
| Working capital | $1.28B | $1.57B | $1.42B | $1.57B | $1.56B | -18.5% |
| Net tangible assets | $2.76B | $3.00B | $2.69B | $2.89B | $3.07B | -7.9% |
| Shares issued | 144.79M | 144.31M | 131.06M | 130.03M | 129.82M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$284.30M | -$320.62M | -$246.51M | -$212.83M | -$166.57M | +11.3% |
| Depreciation & amortisation | $5.93M | $5.85M | $9.80M | $5.20M | $4.99M | +1.2% |
| Stock-based compensation | $41.24M | $37.96M | $36.00M | $35.31M | $36.93M | +8.6% |
| Change in working capital | $673.00K | -$2.91M | -$19.70M | $32.08M | $33.69M | +123.1% |
| Operating cash flow | -$232.47M | -$280.63M | -$224.83M | -$143.31M | -$121.17M | +17.2% |
| Capital expenditure | -$4.57M | -$14.79M | -$8.42M | -$12.05M | -$9.76M | +69.1% |
| Investing cash flow | $147.72M | -$233.41M | $115.13M | $121.17M | $77.74M | +163.3% |
| Financing cash flow | $5.70M | $601.58M | $2.41M | -$3.67M | $2.52M | -99.1% |
| Free cash flow | -$237.04M | -$295.42M | -$233.25M | -$155.35M | -$130.92M | +19.8% |
| End cash position | $184.66M | $262.31M | $175.43M | $282.55M | $308.06M | -29.6% |
Options analytics
Put / call volume
0.97
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
30.00
-55.0% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
3.01K
Contracts, this expiry
Put volume
2.91K
Contracts, this expiry
Heaviest call OI
40.00
0 contracts
Heaviest put OI
30.00
7 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -2.10 | -1.97 | +6.1% |
| Mar 2026 | -1.77 | -2.30 | -29.7% |
| Dec 2025 | -1.50 | -1.80 | -19.7% |
| Sep 2025 | -1.24 | -1.56 | -26.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -2.22 | 6 | $0 | 0.0% |
| Next quarter | -2.25 | 6 | $0 | 0.0% |
| Current year | -8.53 | 6 | $0 | 0.0% |
| Next year | -7.53 | 6 | $87.15M | 0.0% |
Analyst targets & ownership
Mean target$108.63
High target$163.00
Low target$67.00
Implied upside62.86%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy1 / 8
Hold1
Sell / Strong sell0 / 0
Held by insiders0.50%
Held by institutions113.47%
Institutions holding458
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
59.45
+12.19% from price
SMA 20
59.32
+12.45% from price
SMA 50
59.15
+12.77% from price
SMA 100
55.90
+19.32% from price
SMA 200
55.41
+20.38% from price
EMA 12
60.98
+9.39% from price
EMA 26
59.89
+11.36% from price
EMA 50
58.99
+13.07% from price
RSI (14)
60.7
Neutral
MACD (12,26,9)
1.08
Hist 1.08
ATR (14)
5.17
7.75% of price
Realised vol 30D
87.1%
Annualised
Bollinger upper
67.37
20, 2σ
Bollinger lower
51.27
20, 2σ
50 / 200 cross
Golden
59.15 vs 55.41
Trend bias
Above 200
+20.38%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.93
Less volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
87.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-28.0%
Peak to trough
Max drawdown 5Y
-76.2%
Peak to trough
ATR 14
5.17
7.75% of price
Beta (reported)
1.23
5Y monthly, from filing
Short interest
Shares short
16.13M
Prior 14.80M
Change vs prior
+9.0%
Shorts adding
% of float
10.90%
Elevated
% of shares out
10.84%
Against total outstanding
Days to cover
14.6
Crowded exit
Float
136.44M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | BTIG | MAINTAINED | Buy | Buy |
| Oct 5, 26 | Needham | MAINTAINED | Buy | Buy |
| Oct 5, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 28, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Sep 25, 26 | Needham | MAINTAINED | Buy | Buy |
| Feb 26, 26 | BTIG | MAINTAINED | Buy | Buy |
| Feb 2, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Nov 10, 25 | BTIG | MAINTAINED | Buy | Buy |
| Oct 16, 25 | BTIG | MAINTAINED | Buy | Buy |
| Sep 12, 25 | Goldman Sachs | INITIATED | — | Neutral |
| Apr 22, 25 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Apr 8, 25 | Needham | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-05
Corporate Changes & Voting Matters
8-K · 2026-09-03
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-15
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-16
Periodic Financial Reports
10-Q · 2026-05-06
Annual Report to Shareholders
ARS · 2026-04-23
Headlines
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
GlobeNewswire · 2h ago
Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers
Investor's Business Daily · 8h ago
As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)
TIKR · 13h ago
Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results
Quartz · 16h ago
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Zacks · 23h ago
Pfizer’s $6.49 Billion Prevnar Franchise Faces a New Challenger
TIKR · 23h ago
Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial
MarketBeat · 1d ago
NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
Stocktwits · 1d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.